The University of Southampton
University of Southampton Institutional Repository

Afamelanotide for treating erythropoietic protoporphyria

Afamelanotide for treating erythropoietic protoporphyria
Afamelanotide for treating erythropoietic protoporphyria
The company submission (CS) presents evidence of the clinical and cost effectiveness of afamelanotide (SCENESSE®) for adult patients with erythropoietic protoporphyria (EPP) above the age of 18 years old compared to best supportive care. In all studies afamelanotide (16 mg) was given as a subcutaneous implant. The main outcomes measured were duration of tolerance to sunlight and other forms of visible light, phototoxic reactions, health related quality of life (HRQoL) and adverse effects (AEs) of treatment.
erythropoietic protoporphyria
HTA - 16/27/02
National Institute for Health and Care Research
Lord, Joanne
fd3b2bf0-9403-466a-8184-9303bdc80a9a
Onyimadu, Oluchukwu
ff168bd7-1c4f-4756-a34a-7e6b930ae29b
Gaisford, Wendy C.
f1f37a2e-d281-4577-8332-fef0f8b2c789
Rose, Micah J.
f6deee44-f21f-4d14-90a9-f7a449d0adba
Frampton, Geoffrey
26c6163c-3428-45b8-b8b9-92091ff6c69f
Shepherd, Jonathan
dfbca97a-9307-4eee-bdf7-e27bcb02bc67
Lord, Joanne
fd3b2bf0-9403-466a-8184-9303bdc80a9a
Onyimadu, Oluchukwu
ff168bd7-1c4f-4756-a34a-7e6b930ae29b
Gaisford, Wendy C.
f1f37a2e-d281-4577-8332-fef0f8b2c789
Rose, Micah J.
f6deee44-f21f-4d14-90a9-f7a449d0adba
Frampton, Geoffrey
26c6163c-3428-45b8-b8b9-92091ff6c69f
Shepherd, Jonathan
dfbca97a-9307-4eee-bdf7-e27bcb02bc67

Lord, Joanne, Onyimadu, Oluchukwu, Gaisford, Wendy C., Rose, Micah J., Frampton, Geoffrey and Shepherd, Jonathan (2017) Afamelanotide for treating erythropoietic protoporphyria (Health Technology Assessment, HTA - 16/27/02) Southampton. National Institute for Health and Care Research 136pp.

Record type: Monograph (Project Report)

Abstract

The company submission (CS) presents evidence of the clinical and cost effectiveness of afamelanotide (SCENESSE®) for adult patients with erythropoietic protoporphyria (EPP) above the age of 18 years old compared to best supportive care. In all studies afamelanotide (16 mg) was given as a subcutaneous implant. The main outcomes measured were duration of tolerance to sunlight and other forms of visible light, phototoxic reactions, health related quality of life (HRQoL) and adverse effects (AEs) of treatment.

Text
Afamelanotide for treating erythropoietic proroporphyria - Evidence Review Group Report - Version of Record
Download (1MB)
Text
Afamelanotide for treating erythropoietic proroporphyria - Addendum - Version of Record
Download (557kB)

More information

Published date: 26 October 2017
Keywords: erythropoietic protoporphyria

Identifiers

Local EPrints ID: 417747
URI: http://eprints.soton.ac.uk/id/eprint/417747
PURE UUID: cf37ba59-7c4a-4ed0-95ea-34843c38efe7
ORCID for Joanne Lord: ORCID iD orcid.org/0000-0003-1086-1624
ORCID for Oluchukwu Onyimadu: ORCID iD orcid.org/0000-0002-1724-3485
ORCID for Wendy C. Gaisford: ORCID iD orcid.org/0000-0002-2652-8757
ORCID for Geoffrey Frampton: ORCID iD orcid.org/0000-0003-2005-0497
ORCID for Jonathan Shepherd: ORCID iD orcid.org/0000-0003-1682-4330

Catalogue record

Date deposited: 13 Feb 2018 17:30
Last modified: 10 Apr 2024 01:50

Export record

Contributors

Author: Joanne Lord ORCID iD
Author: Wendy C. Gaisford ORCID iD
Author: Micah J. Rose

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×